What conditions does the fda approve lurbinectedin for re treatment?

What FDA-approved “re-treatment” uses does lurbinectedin have?

Lurbinectedin (Zepzelca) is not approved for a general “re-treatment” indication across multiple cancers. The FDA approval described for lurbinectedin is for specific prior-treatment contexts, which function as “re-treatment” in the sense of giving the drug again after earlier therapy.

Which exact cancer and prior-therapy setting is the FDA approval tied to?

The FDA has approved lurbinectedin for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and at least one other line of therapy (for example, after they have received platinum therapy and subsequent treatment). [1]

What does “after progression” mean for re-treatment timing?

The approval is tied to progression following prior treatment, not to a specific number of cycles of lurbinectedin or a set re-treatment interval. Practically, it means the patient’s cancer must have progressed after the earlier approved treatment setting (platinum-based chemotherapy plus additional therapy) to qualify for this use. [1]

Are there other FDA-approved re-treatment conditions beyond metastatic SCLC after platinum-based therapy?

No additional FDA-approved “re-treatment” conditions are stated in the provided source. The approval is specific to metastatic SCLC with the described prior-treatment history. [1]

What if a patient has not had platinum-based chemotherapy or has not had subsequent therapy?

They would not meet the FDA-approved indication as described for lurbinectedin. The specific requirement is progression after platinum-based chemotherapy and at least one other line of therapy. [1]

Sources

1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761203